Objective: Although reactive oxygen species are known to oxidize the sGC heme iron, the basic mechanism(s) governing sGC heme iron recycling to its NO-sensitive, reduced state remain poorly understood.
S oluble guanylate cyclase (sGC), the major cellular receptor for NO, mediates a wide range of physiological effects in the cardiovascular, nervous, and gastrointestinal systems through elevation of the second messenger molecule, cGMP. [1] [2] [3] NO binds to the heme-binding domain of sGC, which stimulates the synthesis of cGMP from guanosine-5′ triphosphate. [4] [5] [6] Although the sGC enzyme and its cGMP product have been successfully targeted for the treatment of cardiovascular diseases, 7 many of the basic mechanisms controlling sGC activity have not been fully elucidated.
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The mammalian sGCs are heterodimeric enzymes consisting of homologous α and β subunits, with α1β1 heterodimer being most highly and ubiquitously expressed. 8, 9 The C termini of both subunits are essential for sGC catalytic activity. 10 The β1 subunit contains an N-terminal H-NOX (heme-NO/ O 2 -binding) domain required for binding NO. 9, [11] [12] [13] The heme iron of sGC is bound to a histidine (His) side chain, and activation occurs when reduced heme iron (Fe 2+ ) binds NO, resulting in cleavage of the His-Fe 2+ bond and formation of a 5-coordinate Fe 2+ with NO on the distal side. Importantly, NO has a reduced affinity for heme iron in its oxidized state (Fe 3+ ), rendering it insensitive to NO. 14, 15 Thus, maintaining sGC heme in the ferrous state is essential for NO/sGC/cGMP signaling. To date, no enzymatic process has been shown to regulate the reduced NO-responsive state of the heme iron.
Nicotinamide adenine dinucleotide (NADH) cytochrome b5 reductase 3 (Cyb5R3) or methemoglobin reductase is a flavoprotein known for its ability to transfer electrons from its NADH domain through the small heme protein partner Cyb5 (cytochrome b5) to a final electron acceptor. Membranerestricted Cyb5R3 in somatic cells regulates several biological reduction reactions, including elongation and unsaturation of fatty acids and lipid metabolism, 16, 17 cholesterol biosynthesis, 18 drug metabolism, 19, 20 and nutrient and oxidative stress responses 21 through Cyb5b, whereas the soluble form of Cyb5R3 reduces erythrocytic methemoglobin through Cyb5a. 22, 23 In previous studies, Cyb5R3 was shown to act as a redox switch controlling the heme iron redox state of α-globin in endothelial cells, thereby modulating NO diffusion and bioavailability in the vascular wall. 24, 25 The presence of Cyb5R3 in vascular smooth muscle cells (VSMCs) was also observed, where it exists in the absence of α-globin expression. 24 Currently, the function of Cyb5R3 in VSMCs is unknown. In this study, we reveal an important role for Cyb5R3 in VSMCs, where it functions as a critical sGC heme iron reductase controlling sGC sensitivity to NO and cGMP levels in VSMCs. Together, these findings advance our knowledge of the basic mechanisms controlling sGC function that may lead to novel and improved therapeutic approaches to treat the decline of cGMP in a wide range of cardiovascular diseases.
Methods
The Extended Methods section is given in the Online Data Supplement.
Cell Culture
Primary rat aortic vascular smooth cells (RASMCs; Lonza) were cultured in Lonza Smooth Muscle Growth Medium-2 supplemented with SmGM-2 SingleQuot kit containing growth factors and 5% fetal bovine serum at 5% CO 2 37°C. For all experiments, cells were cultured up to passage 12. Cells were split with trypsin/EDTA and cultured on tissue culture grade dishes.
cGMP ELISA
RASMCs were cultured in 12-well dishes until confluent and cGMP levels determined via ELISA (Cell Signaling 4360S). Before cGMP measurements, RASMCs were pretreated with 10 μmol/L sildenafil or 100 μmol/L isobutylmethylxanthine for 15 minutes followed by stimulation with diethylammonium
amino]diazen-1-ium-1,2-diolate for 30 minutes or BAY 58-2667 for 1 hour. Baseline measurements were performed after 18-hour treatment with 10 μmol/L sildenafil. All treatments were done at 37°C 5% CO 2 .
Transduction of Aortic Rings and Myography
Aortas from 8-to 10-week-old C57BL/6J mice (Jackson Laboratories) were rapidly excised, cleaned of fat, and cut into 2 mm rings. For chronic inhibition studies, aortic rings were incubated with the Cyb5R3 inhibitor ZINC39395747 (30 μmol/L, 18-24 hours) or transduced with adenovirus containing GFP (green fluorescent protein; 2.4×10 5 copies/mL) or rat Cyb5R3 (2.3×10 7 copies/mL, 18-24 hours) in DMEM (Dulbecco Modified Eagle Medium) media. The next day, rings were placed on a 2-pin myograph (DMT [Danish Myo Technology] , 620 mol/L) filled with physiological salt solution (PSS) containing (in mmol/L): NaCl, 119; KCl, 4.7; MgSO 4 , 1.17; KH 2 PO4, 1.18; d-glucose, 5.5; NaHCO 3 , 25; EDTA, 0.027; CaCl 2 , 2.5; and pH 7.4 when bubbled with 95% O 2 5% CO 2 at 37°C. CaCl 2 was added once PSS pH reached 7.4. After a 30-minute rest, aortas were incrementally stretched to 500 mg initial tension. Viability was tested by the addition of 60 mmol/L KPSS (potassium physiological saline solution) for 15 minutes followed by 3 washes with PSS and allowed to rest for 60 minutes in the presence or absence of 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ). For experiments shown in Figure 6E , aortic rings were rapidly excised and received 30 μmol/L of ZINC39395747 or vehicle followed by 10 μmol/L ODQ for a total of 60 minutes. After the resting or drug incubation period, aortic rings were preconstricted with a cumulative dose response to the prostaglandin mimetic U46619 ) and insensitive to NO.
• Cytochrome b5 reductase 3 (Cyb5R3) is a heme iron reductase and is abundantly expressed in VSMC, yet its function is currently unknown.
What New Information Does This Article Contribute?
• Cyb5R3 expression in VSMC is critical for sGC protein expression, NOstimulated cGMP production, and blood vessel dilation.
• Cyb5R3 sensitizes the sGC enzyme to NO by maintaining the sGC heme iron in its reduced Fe 2+ state.
• Cyb5R3 expression and activity may predict responses to therapies that activate and stimulate the sGC enzyme, as well as therapies that inhibit phosphodiesterases that degrade cGMP.
Loss of sGC protein expression or its sensitivity to NO is associated with cardiovascular disease. In order for NO to signal vessel relaxation and suppress VSMC proliferation, it must react with sGC to increase cGMP production. However, the basic mechanisms that maintain sGC in the NO-sensitive state required for the enzyme's activation are incompletely understood. Here, we uncover a novel function for Cyb5R3 in the regulation of NO signal transduction, cGMP production, and VSMC relaxation. This study provides valuable molecular insights for strategic application of current therapies, as well as the development of new ones, that modulate the sGC/cGMP/phosphodiesterase pathway for improved treatment of cardiovascular disease and many other diseases associated with deficient cGMP levels. 
Results

Endogenous Oxidized sGC Can Be Reduced and Associates With Cyb5R3
ODQ is known to cause sGC heme iron oxidation and results in blunted NO-induced cGMP generation. 26, 27 Previous in vitro studies showed that the chemical reductant dithionite reduces the ODQ-oxidized heme of recombinant sGC, suggesting that sGC can revert to its reduced, NO-sensitive state. 27 On the basis of these studies, we treated primary RASMCs with ODQ for 15 minutes to oxidize the sGC heme iron and examined whether RASMCs can intrinsically reduce oxidized sGC back to the reduced NO-responsive state. As shown in Figure 1A , we found a significant decrease in NO-stimulated cGMP production in the presence of ODQ; however, after ODQ washout and 60 minutes of recovery, we observed complete restoration of NO-stimulated cGMP production. These data suggest that an endogenous sGC heme reduction mechanism exists in RASMCs.
We previously showed that Cyb5R3 controls the heme iron redox state of α-globin in endothelial cells to modulate NO diffusion in the blood vessel wall. 24 In that study, we also noted the presence of Cyb5R3 in VSMCs, where it is expressed in the absence of α-globin. 24 Because Cyb5R3 has no identified function in VSMCs, and sGC has no known heme iron reductase, we hypothesized that Cyb5R3 could serve as an sGC heme reductase. If Cyb5R3 can transfer electrons to reduce oxidized sGC heme iron, it likely forms a protein-protein association when sGC is oxidized. Thus, we conducted experiments using primary RASMCs exposed to ODQ. After ODQ treatment, VSMCs were fixed and subjected to a proximity ligation assay to visualize individual protein-protein interactions between oxidized sGC β and Cyb5R3. Results demonstrate that exposure to ODQ increases the number of sGC β and Cyb5R3 macromolecular complexes ( Figure 1B , red punctates). In addition, we conducted coimmunoprecipitation experiments and found an enhanced association between oxidized sGC β and Cyb5R3 after ODQ treatment ( Figure 1C ). These data suggest oxidized sGC β associates with Cyb5R3 in RASMCs.
Decreased Expression of Cyb5R3, but Not Cyb5b, Reduces sGC Protein Expression and Basal sGC Activity
A previous report showed that oxidation of heme iron in cellular sGC and associated loss of heme results in sGC protein degradation and decreased cGMP levels. 15 Because Cyb5R3 can transfer electrons through the small heme protein Cyb5b, we tested whether genetic knockdown of Cyb5R3 or Cyb5b, as well as pharmacological inhibition of Cyb5R3, modulates sGC α and β expression and basal cGMP levels. Using nontargeting, Cyb5R3 and Cyb5b shRNA lentiviruses to generate stable knockdown in RASMCs, we created cell cultures with >90% knockdown for Cyb5R3 and Cyb5b protein, as assessed by immunoblot (Figure 2A and 2D) and band intensity quantification ( Figure 2B and 2E). Analysis of sGC β protein expression showed a 50% decrease in RASMCs after Cyb5R3 knockdown (Figure 2A and 2B) and a 75% decrease in basal cGMP production compared with nontargeting shRNA RASMCs ( Figure 2C ). We also found a significant decrease in sGC α protein expression (Online Figure IA) . In contrast, no differences in sGC β expression or basal cGMP were observed in Cyb5b knockdown cells ( Figure 2D through 2F ). Using the pharmacological inhibitor of Cyb5R3, ZINC39395747, as previously described, 25 we also observed a significant decrease in sGC β protein expression (>75%) and basal cGMP levels in RASMCs after 24 hours ( Figure 2G and 2I) and sGC α protein expression (Online Figure IB) . We also found that combination of ODQ with Cyb5R3 pharmacological inhibition additively decreased sGC β protein expression (Online Figure IC) . To determine whether loss of Cyb5R3 impacts cellular redox state, we quantified oxidized (glutathione disulfide [GSSG] ) and reduced glutathione (GSH) via isotropic dilution mass spectrometry and found a trend toward decreased GSH levels with no change in GSSG, but a significant decrease in the ratio of GSH/GSSG in Cyb5R3 knockdown RASMCs (Online Figure II) . These data imply that Cyb5R3 expression and activity regulates sGC β protein expression and basal cGMP levels and does not require intermediary electron transfer by Cyb5b.
Decreased Cyb5R3 Expression Limits NOStimulated cGMP Production but Does Not Alter Innate Protein Kinase G Activity
Next, we tested whether genetic loss of Cyb5R3 altered NO-induced cGMP production in RASMCs. Using nontargeting shRNA and Cyb5R3 shRNA-transduced RASMCs, we found a significant decrease in cGMP production when stimulated with the fast-releasing NO donor diethylammo- To test whether this effect was because of an upregulation of another phosphodiesterase, we conducted the same experiments in the presence of the nonselective phosphodiesterase inhibitor, isobutylmethylxanthine, and observed no increase in cGMP after NO stimulation in Cyb5R3-deficient cells (Online Figure IIID) . Because superoxide is known to scavenge NO, we tested whether loss of Cyb5R3 expression increased superoxide levels. We observed a significant decrease in superoxide production, likely indicating that superoxide does not account for the decrease in NO-stimulated cGMP levels ( Figure 3B ). Similar to genetic knockdown, 24 hours inhibition of Cyb5R3 with ZINC39395747 resulted in decreased cGMP levels after stimulation with NO ( Figure 3C ). We observed no direct effects of the Cyb5R3 inhibitor on the ability of sGC to generate cGMP in response to NO using purified sGC (Online Figure  IV) . To probe the effects of decreased Cyb5R3 expression on July 7, 2017 downstream signaling, we first transfected cells with a genetically encoded cGMP biosensor, which harbors the cGMP-sensitive N-terminal domain of protein kinase G (PKG) linked to a circularly permuted eGFP (enhanced green fluorescence protein). 28 After transfection into nontargeting shRNA and Cyb5R3 shRNA-transduced RASMCs, cells were stimulated with diethylammonium (Z)-1-(N,N-diethylamino) diazen-1-ium-1,2-diolate, and increases in fluorescence were captured using high-speed confocal microscopy. Consistent with a loss of cGMP, we observed a significant reduction in fluorescence in Cyb5R3 knockdown compared with control RASMCs ( Figure 3D ).
cGMP production is known to activate PKG and phosphorylate a host of downstream proteins. Among the downstream targets of PKG is VASP (vasodilator-stimulated phosphoprotein), a protein implicated in the control of cytoskeletal dynamics and cell migration. PKG selectively activates VASP by phosphorylation on serine 239 (p-VASP 239 ). 29 Therefore, we determined whether loss of Cyb5R3 protein expression influences p-VASP 239 after NO stimulation 
, lysed, and subjected to cGMP measurements via ELISA (n=3). B, Primary RASMCs were treated with ODQ (10 μmol/L, 10 min) and fixed in paraformaldehyde. Cells were then subjected to a proximity ligation assay to measure sGC/Cyb5R3 macromolecular complexes (red punctates) using confocal microscopy. IgG antibody served as a negative control. Green labeling is smooth muscle actin, and blue is nuclei. Images on right show zoomed in areas (in white box) from images on the left. Quantification is from 10 images, and complexes were normalized per nuclei as shown in graph. C, RASMCs were treated with and without ODQ (10 μmol/L, 15 min), followed by coimmunoprecipitation of sGC β using a rabbit anti-sGC β antibody. Lysates were blotted for Cyb5R3 using a goat anti-Cyb5R3 followed by a LI-COR anti-goat 700 secondary antibody (red channel), and sGC β using a rabbit anti-sGC β followed by an LI-COR antirabbit 800 secondary antibody (green channel). Merge channels are shown in bottom. Total cell lysate input or pull down using IgG or anti-sGC β is shown for each condition. Cyb5R3 band density normalized to sGC β is shown in graph on right (n=3). *P<0.05, **P<0.01, ***P<0.001, and ***P<0.0001 using a 1-way ANOVA (A) or a Student t test (B and C) and error bars are SEM.
using immunoblot analysis in nontargeting shRNA and Cyb5R3 shRNA RASMCs treated with diethylammonium
-diolate Consistent with decreased cGMP levels, p-VASP 239 levels were also significantly decreased with the loss of Cyb5R3 ( Figure 3E ). To determine whether loss of p-VASP 239 after NO stimulation was because of dysfunctional PKG activity, we stimulated Cyb5R3-deficient RASMCs with the cell-permeable cGMP analog, 8-bromo-cGMP. We observed complete phosphorylation of VASP 239 , suggesting that PKG activity remained functional ( Figure 3F ). Together, these data suggest that loss of Cyb5R3 expression decreases NO-stimulated cGMP production but does not influence innate PKG activity in RASMCs.
Cyb5R3 Expression and Activity Modulates Responsiveness to sGC Stimulator and Activator Treatment
Because NO-stimulated cGMP production was severely blunted in Cyb5R3-deficient cells, we tested whether a heme-dependent sGC stimulator (BAY 41-2272), which synergizes with NO to increase cGMP, could rescue cGMP levels in Cyb5R3 knockdown cells. We observed that BAY 41-2272 restored ≈15% of the NO-stimulated cGMP in Cyb5R3-deficient cells compared with nontargeting shRNA Figure 2 . Loss of cytochrome b5 reductase 3 (Cyb5R3) expression or activity, but not Cyb5b, causes Soluble guanylate cyclase (sGC) β protein loss and decreased basal cGMP levels. A, Rat aortic vascular smooth cells (RASMCs) were transduced with lentivirus to express nontargeting shRNA (nt shRNA) or Cyb5R3 shRNA. After 7 days of selection, cells were lysed and Western blotted for Cyb5R3, sGC β, Cyb5b, and α-tubulin expression. B, Quantification of Western blot on left (n=4). C, Accumulation of cGMP levels from nt shRNAand Cyb5R3 shRNA-transduced RASMCs treated with sildenafil (10 μmol/L, 18 h; n=4). D, Western blot of Cyb5R3, sGC β, Cyb5b, and α-tubulin expression from RASMCs transduced with nt shRNA or Cyb5b shRNA. E, Quantification of Western blot on left (n=3) and (F) basal cGMP levels (n=4). G, Cyb5R3, sGC β, Cyb5b, and α-tubulin expression from RASMCs treated with the ZINC39395747 (30 μmol/L, 24 h), H, Protein quantification from blot on left (n=3) and (I) basal cGMP levels (n=3). *P<0.05, ***P<0.001, and ****P<0.0001 using a Student t test and error bars are SEM. July 7, 2017
RASMCs treated with BAY 41-2272 and NO (Online Figure  V) . Because we could not completely rescue NO-stimulated cGMP signaling with BAY 41-2272, we tested whether Cyb5R3 might regulate sGC β heme iron redox state. It is known that sGC oxidation can lead to apo-sGC β formation and that the heme-replacing sGC activator, BAY 58-2667, increases cGMP production. 15 Therefore, we conducted a dose response to BAY 58-2667 in nontargeting shRNAor Cyb5R3 shRNA-transduced RASMCs. We observed a greater BAY 58-2667 concentration-dependent increase in cGMP in Cyb5R3 shRNA-transduced RASMCs compared with nontargeting shRNA RASMCs ( Figure 4A) . A similar trend was observed after 24 hours treatment with the Cyb5R3 inhibitor ZINC39395747 in naïve RASMCs ( Figure 4B ). Next, we treated naïve RASMCs with a fixed dose of ODQ and increasing concentrations of ZINC39395747 for 1 hour, followed by BAY 58-2667 stimulation. The combination of ODQ and increasing concentrations of Cyb5R3 inhibitor resulted in an additive effect of cGMP production after BAY 58-2667 stimulation, likely indicating active sGC reduction by Cyb5R3 during sGC oxidation in RASMCs ( Figure 4C ). This result was not caused by acute Cyb5R3 inhibition alone because BAY 58-2667 stimulation showed no significant increase in cGMP (Online Figure VIA) . Furthermore, acute oxidant challenge with antimycin A, a mitochondrial cytochrome c reductase inhibitor that increases superoxide production or hydrogen peroxide in the presence of the Cyb5R3 inhibitor, caused a significant increase in cGMP after BAY 58-2667 stimulation (Online Figure VIB) . To determine the effect of increased Cyb5R3 expression on sGC oxidation, we transduced RASMCs with a rat Cyb5R3 adenovirus for 24 hours followed by a 30-minute treatment with ODQ. Overexpression efficiency is shown in Online Figure VII . After stimulation with BAY 58-2667, we found suppressed cGMP levels with Cyb5R3 overexpression and ODQ ( Figure 4D ). Together, these data indicate that Cyb5R3 modulates responsiveness to sGC stimulator and activator treatment.
Cyb5R3 Directly Reduces Oxidized sGC
Because our cell culture studies indicate that Cyb5R3 may regulate sGC heme iron redox state, we tested whether Cyb5R3 directly reduces oxidized sGC β and sensitizes sGC β to NO. Using purified human recombinant Cyb5R3/Cyb5b and human sGC, we first subjected samples to an in vitro cGMP assay. Results show that Cyb5R3 sensitizes sGC to NO resulting in augmented production of cGMP ( Figure 5A , green bars). This effect was dependent on Cyb5R3 activity because ZINC39395747 (red bar) blunted this response. Consistent with the cell culture data, this reaction does not require Cyb5b. The chemical reductant, dithiothreitol, served as a positive control. Conversely, BAY 58-2667, which increases sGC activity when sGC is heme deficient, showed the opposite effect of NO ( Figure 5B ). The absence of NADH in Cyb5R3 and oxidized sGC competent conditions resulted in a lack of responsiveness to both NO and BAY 58-2667 (open bars).
Next, we conducted UV-Vis (ultraviolet-visible) spectral analysis to directly measure conversion of ferric sGC to ferrous sGC using purified proteins. We observed a time-dependent change in reduction of oxidized sGC to reduced sGC in the presence of Cyb5R3 and NADH with a rate constant of 1.56×10 −4 mol/L −1 min −1 ( Figure 5C and 5D) . Collectively, these results suggest that Cyb5R3 directly reduces oxidized sGC resulting in sensitization to NO.
Inhibition of Cyb5R3 Activity or Overexpression of Cyb5R3 Modulates BAY 58-2667-Induced Relaxation in Mouse Thoracic Aortas
Previous work demonstrated that acetylcholine-mediated aortic vasodilation is driven by NO production from endothelium. 30 Therefore, we extended our biochemical and cell culture studies to ex vivo aortic ring assays to study the role of Cyb5R3 in acetylcholine, SNP, and BAY 58-2667-stimulated aortic relaxation. To do so, we inhibited Cyb5R3 with ZINC39395747 or transduced arteries with an adenovirus to overexpress GFP or rat Cyb5R3. Figure 6A shows overexpression of GFP or Cyb5R3, and Figure 6B shows transduction in the aortic medial 1 h; n=4) . D, RASMCs were transduced with GFP (green fluorescent protein) or rat Cyb5R3 adenovirus (AV) for 24 h followed by ODQ treatment for 60 min. After 60 min, cells were then treated with sildenafil (10 μmol/L, 15 min), followed by BAY 58-2667 (100 nmol/L, 60 min) stimulation and subjected to a cGMP ELISA assay (n=3-4). *P<0.05, **P<0.01, and ****P<0.0001 using a 1-way ANOVA and error bars are SEM.
layers. For acetylcholine and SNP studies, aortas were incubated overnight with ZINC39395747, washed, and mounted on a 2-pin myograph. Responses to acetylcholine ( Figure 6C ) or SNP ( Figure 6D ) showed significantly impaired relaxation. Next, we tested whether acute inhibition of Cyb5R3 in the presence of ODQ modulated responsiveness to BAY 58-2667. Results show that Cyb5R3 inhibition enhanced the response to BAY 58-2667-induced relaxation ( Figure 6E ). To test the effects of Cyb5R3 overexpression, we incubated thoracic aortic rings with GFP or rat Cyb5R3 adenovirus for 24 hours and performed cumulative dose response to BAY 58-2667 in the presence of ODQ. We found that overexpression of Cyb5R3 reduced BAY 58-2667-mediated relaxation in the presence of ODQ ( Figure 6F ). These results suggest that Cyb5R3 modulates NO and BAY 58-2667-induced relaxation in mouse thoracic aortas.
Discussion
NO is the primary activator of the VSMC sGC/cGMP/PKG pathway in humans and animal models.
1-3,30-34 The major prerequisite for NO-induced sGC activation is reduced heme iron (Fe 2+ ) in the sGC β H-NOX domain. sGC heme iron oxidation (Fe 3+ ) abolishes NO-induced sGC-mediated cGMP production. Although it is clear that cellular sGC can exist in the oxidized state, the physiological mechanisms regulating sGC heme redox recycling remain largely unknown. Through a combination of genetic and pharmacological approaches, we reveal that Cyb5R3 associates with ferric sGC and directly reduces sGC heme iron from Fe 3+ to Fe
2+
, and by doing so, sensitizes sGC to NO to generate cGMP and cause vasodilation (Figure 7) . Notably, these novel data unveil a central mechanism regulating sGC function in VSMCs, a mechanism conceivably operative in multiple cell types and physiological processes.
Under normal physiological conditions, sGC exists predominantly in the reduced, NO-sensitive redox state; however, a shift in oxidized and heme-free forms ensue in numerous diseases.
15,35-37 Critical factors driving sGC oxidation are reactive oxygen species, including superoxide and peroxynitrite. 15 ,38 Figure 5 . Cytochrome b5 reductase 3 (Cyb5R3) directly reduces oxidized soluble guanylate cyclase (sGC). A and B, Recombinant human Cyb5R3 (10 μmol/L), Cyb5b (10 μmol/L), and human oxidized sGC (500 ng) were combined and incubated in 250 mmol/L triethanolamine buffer, 1 mmol/L dithiothreitol (DTT; positive control), ZINC39395747 (50 μmol/L), ±100 μmol/L nicotinamide adenine dinucleotide (NADH; required cofactor for Cyb5R3) in the absence of oxygen. Samples were then combined with GTP (guanosine triphosphate; 100 μmol/L), and Mn 2+ (1 mmol/L) followed by stimulation with diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEA NONOate; 1 μmol/L) or BAY 58-2667 (1 μmol/L). After 5 min, reactions were stopped, and cGMP was measured (n=3). C and D, UV-Vis (ultraviolet-visible) spectra showing time-dependent reduction of oxidized sGC by mixing purified Cyb5R3 (5 μmol/L) and sGC (1 μmol/L) in the presence of NADH (10 μmol/L). *P<0.05 using a 1-way ANOVA and error bars are SEM. Figure 6 . Inhibition of cytochrome b5 reductase 3 (Cyb5R3) activity or overexpression of Cyb5R3 modulates BAY 58-2667-induced vasodilation in mouse thoracic aortas. A, Western blot of GFP (green fluorescent protein) and Cyb5R3 from pooled mouse thoracic aortas transduced with GFP or rat Cyb5R3 adenovirus (AV; n=3-5). B, Immunofluorescence images show GFP (green), Cyb5R3 (red), and nuclei (blue) in medial layers after GFP and rat Cyb5R3 AV overexpression. C, Cumulative dose-response curve to acetylcholine (Ach) or (D) sodium nitroprusside (SNP) 24 h after Cyb5R3 inhibition (n=8-10). E, Isolated thoracic aorta segments were mounted on a 2-pin myograph and incubated with ZINC39395747 and 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ). After 60 min, aortas were subjected to cumulative doses of BAY 58-2667 shown in graph (n=5-7 vessels). F, Isolated thoracic aortic rings were incubated with GFP or Cyb5R3 AV for 24 h, mounted on a 2-pin myograph and subjected to cumulative doses of BAY 58-2667 (n=6 vessels). *P<0.05, **P<0.01, and ****P<0.0001 using a 2-way ANOVA and error bars are SEM.
A previous study identified conditions manifesting sGC oxidation and showed that reduction of ODQ-oxidized sGC with dithionite has identical NO-stimulated activation as the original reduced sGC. 27 In addition, a previous report showed that oxidation of sGC with NS2028 is slowly reversible, suggesting that an endogenous mechanism exists to resensitize sGC to NO. 39 To test whether an sGC redox system exists in RASMCs, we treated cells with ODQ, followed by a washout period. We observed complete restoration of NO-stimulated cGMP in a time frame insufficient for new sGC protein synthesis, providing evidence that an active cellular sGC redox system exists to reduce oxidized sGC in RASMCs.
Our recent work showed that Cyb5R3 regulates α-globin heme redox state in small artery and arteriolar endothelial cells to control NO diffusion. 24 In that study, we also observed abundant expression of Cyb5R3 in VSMCs. Despite this observation, there are currently no published reports identifying a function for Cyb5R3 in VSMCs. The rich expression of Cyb5R3 in VSMCs suggested to us that it could be an sGC reductase for 2 reasons: (1) there is a major dissimilarity in redox potential for sGC (+187 mV) and Cyb5R3 (−265 mV), 40, 41 signifying that this redox differential favorably supports Cyb5R3 as a potential sGC reductase, and (2) the sGC β knockout mouse model has a 60% reduced life expectancy, severe growth retardation, gastrointestinal complications, and neurological pathologies, 3, 42 all of which mirror the complications in humans with Cyb5R3 deficiency. 43 On the basis of this evidence, we investigated whether Cyb5R3 and sGC form a protein-protein complex to facilitate a specific and tightly coordinated electron transfer. We found oxidized sGC β associates with Cyb5R3 in RASMCs using proximity ligation assay and immunoprecipitation assays. Although these data cannot distinguish between direct proteinprotein binding and stable versus transient associations, it does provide credible evidence for the formation of a macromolecular complex between Cyb5R3 and oxidized sGC β. Although we predict that Cyb5R3 may directly couple to the H-NOX domain of sGC to transfer electrons, studies are warranted for determining molecular patterning of Cyb5R3-sGC complex assembly and identification of additional known protein interacting partners, such as disulfide isomerase, CCTeta (chaperonin containing T-complex polypeptide subunit eta), and G-protein signaling modulator-2 that are important for this process. [44] [45] [46] [47] Furthermore, it is unclear why membrane-bound Cyb5R3 interacts and regulates cytosolic expressed sGC. Because Cyb5R3 resides on the plasma membrane, endoplasmic reticulum, and mitochondria in a cytosol-facing orientation, we speculate that Cyb5R3 may spatially and temporally regulate sGC heme iron redox state to modulate various compartmentalized signaling events. Future studies designed to partition Cyb5R3 to various subcellular compartments would provide key evidence to address these questions.
Previous reports demonstrated that cellular sGC β heme iron oxidation and loss of heme results in apo-sGC β protein degradation and decreased cGMP levels via a CHIP (C terminus of heat shock cognate protein 70 interacting protein)-dependent mechanism. 48, 49 After decreased Cyb5R3 activity or expression, we observed a significant loss of sGC β and sGC α. This was accompanied by a ≈70% decrease in basal cGMP levels. However, this effect was not observed after Cyb5b knockdown. Although hemoglobin and other hemoproteins or chemical reduction reactions rely on electron transfer through Cyb5, sGC reduction does not. This is reminiscent of Cyb5R3 function at the plasma membrane, 50, 51 where it serves as a critical CoQ (co-enzyme Q) reductase to protect the plasma membrane from lipid peroxidation independent of Cyb5b. The major difference in redox potential (sGC, +187 mV versus Cyb5R3, -265 mV) may explain why Cyb5b is not required and why coupling between Cyb5R3 and sGC β occurs. It is also possible that subcellular Cyb5R3 membrane pools devoid of Cyb5b expression exist that may specifically regulate sGC reduction.
Consistent with the loss of basal cGMP, we also found ≈90% decrease in NO-stimulated cGMP signaling and suppressed PKG activation. However, the capacity to activate PKG was independent of loss of Cyb5R3 protein expression as 8-bromo-cGMP was able to fully phosphorylate VASP 239 , suggesting that intrinsic PKG activity is likely unaffected. Because Cyb5R3 is a heme iron reductase for other proteins, we tested whether this loss of cGMP was because of heme iron oxidation. Because BAY 58-2667 preferentially activates heme-deficient sGC as a result of sGC oxidation, we used it in Cyb5R3 gain-of-function and loss-of-function studies in both cell-based and ex vivo artery preps. We observed enhanced responses to BAY 58-2667 in Cyb5R3-deficient cells, suggesting that it may regulate sGC heme iron redox status. Time-resolved changes in the UV-Vis spectra of the experimental system containing only purified Cyb5R3 and sGC confirm that Cyb5R3 can directly reduce oxidized sGC, providing evidence that this mechanism is likely operable in cells. A limitation to our studies is that we cannot directly measure sGC heme redox state in cells. It is possible that Cyb5R3/ sGC coupling allows for modulation of sGC heme redox state by preventing heme release and formation of apo-sGC β. Development of sGC heme iron redox biosensors is needed to directly answer this question.
In our previous work, we reported that acute inhibition (1 hour) of Cyb5R3 activity with ZINC3939574 resulted in increased cGMP production in a vascular cell coculture model composed of endothelium and smooth muscle. 25 These effects were attributed to the ability of Cyb5R3 to regulate α-globin heme iron reduction after NO dioxygenation. However, Figure 7 . Schematic of cytochrome b5 reductase 3 (Cyb5R3) regulating soluble guanylate cyclase (sGC) heme redox state. Illustration shows that Cyb5R3 sensitizes sGC to NO by reducing the sGC heme iron, controlling cGMP production and vessel relaxation.
in this study, we find that chronic inhibition of Cyb5R3 (24 hours) in isolated smooth muscle cells induced a loss of NOstimulated cGMP production through sGC heme iron oxidation. The difference in NO-stimulated cGMP production after acute versus chronic Cyb5R3 inhibition is likely reflected in the basic biochemistry of NO reacting with the heme center of globins versus sGC. Oxygen-bound ferrous hemoglobin α and cytoglobin react with NO and oxidize to NO 3 − (NO dioxygenation), and result in ferric heme iron formation at a rate constant of ≈10 7 mol/L −1 S −1
. 52 Unlike globins, sGC does not bind oxygen and, therefore, does not facilitate NO dioxygenation and heme oxidation. 53, 54 Furthermore, the lack of an oxyferrous heme complex represses sGC auto-oxidation. Because basal NO production is constant in the vessel wall, the rate of globin heme oxidation is fast once Cyb5R3 is blocked, whereas the rate of sGC oxidation is slow. In Online Figure  VIA , we demonstrate no difference in BAY 58-2667 response after 1 and 3 hours of Cyb5R3 inhibition with ZINC3939574, consistent with the hypothesis that sGC oxidation is slow after Cyb5R3 inhibition in a physiological setting. However, this process can occur under prolonged Cyb5R3 inhibition or be accelerated by a pro-oxidant challenge, as shown in Figure 4C or Online Figure VIB . Therefore, it is important to note that biochemistry and rates of oxidation likely explain the differences in the cell signaling and physiological responses.
The ability for Cyb5R3 to regulate sGC heme iron reduction and potentially other sGC regulatory functions is not mutually exclusive. For example, it is possible that Cyb5R3 may directly or indirectly regulate sGC cysteines through posttranslational S-nitrosation, modifications that confer sGC desensitization 55 or modulate cysteine redox state during oxidant challenge. More studies are needed to address these other potential functions/events. Previous work has demonstrated that Cyb5R3 also regulates cytosolic NAD + /NADH ratios, 21 which are known to contribute to gene regulation and protein acetylation via the sirtuins for example. Modulating NAD + / NADH ratios through expression of Cyb5R3 may also directly or indirectly impact sGC/cGMP signaling through metabolic pathways. In addition, Cyb5R3 may contribute to the maturation of sGC itself by participating in the heme insertion and reduction process and possibly protein folding. 56 Last, it has been reported that H 2 S can reduce oxidized sGC 57 ; however, it is unknown whether Cyb5R3 impacts this pathway. Future work dedicated to understanding the broad impact of Cyb5R3 on sGC/cGMP is warranted.
Although this study is the first to identify a critical role for Cyb5R3 in cGMP signaling, it may have extensive implications for many current and developing NO-, sGC-, and phosphodiesterase-targeted therapies to treat human disease. For example, changes in Cyb5R3 expression or polymorphisms that modulate Cyb5R3 activity may influence sGC therapeutic responsiveness. It is possible that changes in Cyb5R3 activity may better predict responsiveness to sGC activator therapy, compared with sGC stimulator or phosphodiesterase therapy. Although this body of work was limited to biochemical, cellular, and ex vivo studies, future studies determining the in vivo role of Cyb5R3 are needed to translate these results and to determine the potential for predicting clinical responsiveness to NO, sGC, and phosphodiesterase therapies.
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